Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference

 Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare
                                  Conference

Presentation Scheduled for Wednesday, February 27th at 2:15 PM ET

PR Newswire

NEW YORK, Feb. 22, 2013

NEW YORK, Feb. 22, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc.
(Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive
Officer, will be presenting at the Citigroup 2013 Global Healthcare
Conference, being held February 25-27, 2013, in New York City. Mr. Bentsur's
presentation is scheduled to take place on Wednesday, February 27^th, at 2:15
PM ET.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the
Investor Information page of the Company's Website at
http://investors.keryx.com. An archived version of the webcast will be
available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3
clinical program for the treatment of hyperphosphatemia (elevated phosphate
levels) in patients with end-stage renal disease, conducted pursuant to a
Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to
submit an NDA with the FDA and a MAA with the EMA in the second quarter of
2013. Zerenex is also in Phase 2 development in the U.S. for the management
of phosphorus and iron deficiency in anemic patients with Stage 3 to 5
non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its
New Drug Application for marketing approval of ferric citrate in Japan for the
treatment of hyperphosphatemia in patients with chronic kidney disease. Keryx
is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.
 
Press spacebar to pause and continue. Press esc to stop.